

Mioara Larion

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5753925/publications.pdf>

Version: 2024-02-01

37
papers

1,302
citations

471509

17
h-index

414414

32
g-index

39
all docs

39
docs citations

39
times ranked

1901
citing authors

#	ARTICLE	IF	CITATIONS
1	Cysteine is a limiting factor for glioma proliferation and survival. <i>Molecular Oncology</i> , 2022, 16, 1777-1794.	4.6	7
2	Cryo-EM structures reveal multiple stages of bacterial outer membrane protein folding. <i>Cell</i> , 2022, 185, 1143-1156.e13.	28.9	45
3	Magnetic resonance spectroscopy for the study of CNS malignancies. <i>Progress in Nuclear Magnetic Resonance Spectroscopy</i> , 2021, 122, 23-41.	7.5	19
4	DDRE-20. TARGETING SPHINGOLIPID PATHWAY REVEALS VULNERABILITY IN IDH1MUT GLIOMA. <i>Neuro-Oncology Advances</i> , 2021, 3, i10-i10.	0.7	0
5	TBMT-02. APOLLO: RAMAN-BASED PATHOLOGY OF MALIGNANT GLIOMA. <i>Neuro-Oncology Advances</i> , 2021, 3, i20-i20.	0.7	0
6	A Single-Organelle Optical Omics Platform for Cell Science and Biomarker Discovery. <i>Analytical Chemistry</i> , 2021, 93, 8281-8290.	6.5	11
7	Reversing Epigenetic Gene Silencing to Overcome Immune Evasion in CNS Malignancies. <i>Frontiers in Oncology</i> , 2021, 11, 719091.	2.8	14
8	IDH1 mutations induce organelle defects via dysregulated phospholipids. <i>Nature Communications</i> , 2021, 12, 614.	12.8	44
9	Metabolic reprogramming associated with aggressiveness occurs in the G-CIMP-high molecular subtypes of IDH1mut lower grade gliomas. <i>Neuro-Oncology</i> , 2020, 22, 480-492.	1.2	31
10	Sphingolipid Pathway as a Source of Vulnerability in IDH1mut Glioma. <i>Cancers</i> , 2020, 12, 2910.	3.7	13
11	Metabolic plasticity of IDH1-mutant glioma cell lines is responsible for low sensitivity to glutaminase inhibition. <i>Cancer & Metabolism</i> , 2020, 8, 23.	5.0	14
12	Metabolic Landscape of a Genetically Engineered Mouse Model of IDH1 Mutant Glioma. <i>Cancers</i> , 2020, 12, 1633.	3.7	11
13	Triptolide suppresses IDH1-mutated malignancy via Nrf2-driven glutathione metabolism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 9964-9972.	7.1	85
14	IDH mutation in glioma: molecular mechanisms and potential therapeutic targets. <i>British Journal of Cancer</i> , 2020, 122, 1580-1589.	6.4	301
15	Targeting Glycolysis through Inhibition of Lactate Dehydrogenase Impairs Tumor Growth in Preclinical Models of Ewing Sarcoma. <i>Cancer Research</i> , 2019, 79, 5060-5073.	0.9	86
16	Toward Single-Organelle Lipidomics in Live Cells. <i>Analytical Chemistry</i> , 2019, 91, 11380-11387.	6.5	20
17	Using Electron Microscopy to Enhance the Knowledge of Biological Systems. <i>Microscopy and Microanalysis</i> , 2019, 25, 1164-1165.	0.4	0
18	Retinoid receptor turnover mediated by sumoylation, ubiquitination and the valosin-containing protein is disrupted in glioblastoma. <i>Scientific Reports</i> , 2019, 9, 16250.	3.3	11

#	ARTICLE	IF	CITATIONS
19	Detection of Metabolic Changes Induced via Drug Treatments in Live Cancer Cells and Tissue Using Raman Imaging Microscopy. <i>Biosensors</i> , 2019, 9, 5.	4.7	11
20	Novel Targeting of Transcription and Metabolism in Glioblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 1124-1137.	7.0	45
21	Protein phosphatase 2A inhibition enhances radiation sensitivity and reduces tumor growth in chordoma. <i>Neuro-Oncology</i> , 2018, 20, 799-809.	1.2	18
22	DRES-18. SUMO1 AND VALOSIN-CONTAINING PROTEIN REGULATE RETINOID RECEPTOR PROTEIN TURNOVERâ€“ A PROCESS DISRUPTED IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi79-vi79.	1.2	0
23	EXTH-58. ONC206, AN IMPRIDONE FAMILY MEMBER, SUPPRESSES GLIOBLASTOMA CELLS VIA BLOCKING CANCER STEMNESS PATHWAYS. <i>Neuro-Oncology</i> , 2018, 20, vi97-vi97.	1.2	0
24	BCAbox Algorithm Expands Capabilities of Raman Microscope for Single Organelles Assessment. <i>Biosensors</i> , 2018, 8, 106.	4.7	15
25	Hypoxia in the glioblastoma microenvironment: shaping the phenotype of cancer stem-like cells. <i>Neuro-Oncology</i> , 2017, 19, 887-896.	1.2	196
26	Kinetic Cooperativity in Human Pancreatic Glucokinase Originates from Millisecond Dynamics of the Small Domain. <i>Angewandte Chemie</i> , 2015, 127, 8247-8250.	2.0	7
27	Kinetic Cooperativity in Human Pancreatic Glucokinase Originates from Millisecond Dynamics of the Small Domain. <i>Angewandte Chemie - International Edition</i> , 2015, 54, 8129-8132.	13.8	29
28	Conformational heterogeneity and intrinsic disorder in enzyme regulation: Glucokinase as a case study. <i>Intrinsically Disordered Proteins</i> , 2015, 3, e1011008.	1.9	10
29	Dual allosteric activation mechanisms in monomeric human glucokinase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 11553-11558.	7.1	46
30	Role of connecting loop I in catalysis and allosteric regulation of human glucokinase. <i>Protein Science</i> , 2014, 23, 915-922.	7.6	11
31	Orderâ€“Disorder Transitions Govern Kinetic Cooperativity and Allostery of Monomeric Human Glucokinase. <i>PLoS Biology</i> , 2012, 10, e1001452.	5.6	51
32	Homotropic allosteric regulation in monomeric mammalian glucokinase. <i>Archives of Biochemistry and Biophysics</i> , 2012, 519, 103-111.	3.0	35
33	Distance and dynamics determination by W-band DEER and W-band ST-EPR. <i>European Biophysics Journal</i> , 2010, 39, 711-719.	2.2	9
34	Direct Evidence of Conformational Heterogeneity in Human Pancreatic Glucokinase from High-Resolution Nuclear Magnetic Resonance. <i>Biochemistry</i> , 2010, 49, 7969-7971.	2.5	29
35	Global Fit Analysis of Glucose Binding Curves Reveals a Minimal Model for Kinetic Cooperativity in Human Glucokinase. <i>Biochemistry</i> , 2010, 49, 8902-8911.	2.5	23
36	23-Residue C-Terminal Î±-Helix Governs Kinetic Cooperativity in Monomeric Human Glucokinase. <i>Biochemistry</i> , 2009, 48, 6157-6165.	2.5	23

#	ARTICLE	IF	CITATIONS
37	Divergent Evolution of Function in the ROK Sugar Kinase Superfamily: Role of Enzyme Loops in Substrate Specificity. <i>Biochemistry</i> , 2007, 46, 13564-13572.	2.5	30